Korro Bio (KRRO) Common Equity (2018 - 2026)

Korro Bio's Common Equity history runs 9 years deep, the most recent figure standing at $119.6 million for Q1 2026.

• Quarterly Common Equity fell 13.91% year-over-year to $119.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.6 million (down 13.91% YoY) and the FY2025 annual result came in at $51.4 million, down 67.93% from the prior year.
• Common Equity was $119.6 million for Q1 2026 at Korro Bio, up from $51.4 million in the prior quarter.
• Across five years, Common Equity topped out at $198.1 million in Q2 2024 and bottomed at -$153.3 million in Q3 2023.
• A 5-year average of $68.7 million and a median of $112.7 million in 2022 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 271.57% in 2023, while the deepest fall reached 286.96% in 2023.
• Korro Bio's Common Equity stood at -$99.0 million in 2022, then surged by 271.57% to $169.9 million in 2023, then retreated by 5.59% to $160.4 million in 2024, then plunged by 67.93% to $51.4 million in 2025, then soared by 132.57% to $119.6 million in 2026.
• Business Quant data shows KRRO's Common Equity at $119.6 million in Q1 2026, $51.4 million in Q4 2025, and $99.0 million in Q3 2025.